LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial 87.5% of patients treated with LYNPARZA were alive at six ...

Maintenance therapy with Lynparza plus cediranib did not significantly improve progression-free survival (PFS) or overall survival (OS) compared to Lynparza alone in patients with relapsed ...

Lynparza ® (olaparib) is a targeted therapy indicated for the treatment of adults with advanced ovarian cancer, deleterious or suspected deleterious germline BRCA mutated (gBRCAm) HER2-negative ...

Study highlights: The combination of Lynparza, Zytiga and prednisone demonstrated better outcomes in terms of progression-free survival and response rates compared to using Lynparza or Zytiga alone ...

You may be able to get a 90-day supply of Lynparza. If approved by your insurance company, getting a 90-day supply of the drug could reduce your number of trips to the pharmacy and help lower the ...

AstraZeneca and Merck & Co.’s Lynparza may have claimed a broad trial success—and European approval—in prostate cancer, but the FDA has its reservations.

Learn about side effects, uses, cost, and more for Lynparza (olaparib). It’s a prescription drug used to treat certain kinds of cancer in adults.

Lynparza is a prescription drug used to treat certain types of prostate, ovarian, breast, and pancreatic cancer. Learn about the drug’s dosages, form, and more.

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck. The drug generated product sales of $2.35 for AstraZeneca in 2021, and alliance revenues of $989 million for Merck.

Call your doctor right away if you think you’ve taken too much Lynparza. You can also call 800-222-1222 to reach the American Association of Poison Control Centers or use their online resource ...

AstraZeneca Plc's (AZN.L) drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.

LYNPARZA is the first and only PARP inhibitor approved in Japan in mCRPC. Prostate cancer is the third most common type of cancer in Japan and in 2020, accounted for over 100,000 new cases.